Biomarkers of the responses to individual treatments and statistical significances are listed in Figure 6I. Two primary AMLs carried TP53 gene mutations, one in a FLT3 wild-type AML (A1) and the other in a FLT3-TKD AML (A2). Here, FLT3 is linked to acute myeloid leukemia.